Physician profile
Kenneth Mills
NPI 1023016292
$3,779.08
in general payments reported to CMS, 2019-2025
20 companies · $1,089 in 2025
The $1,089 reported for 2025 was more than what 86% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,040 · 2020: $299 · 2022: $106 · 2023: $397 · 2024: $849 · 2025: $1,089.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,317 · Education: $17.36.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,316.92 |
| Education | $17.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $1,691.57 | 2019-2025 | Rukobia, Cabenuva, Dovato |
| Gilead Sciences, INC. | $555.02 | 2019-2025 | Sunlenca, Biktarvy |
| Merck Sharp & Dohme LLC | $546.96 | 2019-2025 | Pifeltro, Delstrigo, Dificid |
| Theratechnologies INC. | $164.50 | 2022-2025 | Trogarzo, Egrifta |
| Abbvie INC. | $149.31 | 2023-2025 | |
| Janssen Biotech, INC. | $117.71 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $92.37 | 2020-2024 | Farxiga, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $90.95 | 2019 | |
| Pfizer INC. | $87.89 | 2019-2025 | |
| Allergan, INC. | $42.52 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $38.45 | 2019 | |
| Glaxosmithkline, LLC. | $34.27 | 2019-2025 | Arexvy, Shingrix |
| Astellas Pharma US INC | $29.86 | 2025 | Veozah |
| Regeneron Healthcare Solutions, INC. | $26.98 | 2019 | |
| Daiichi Sankyo INC. | $22.59 | 2019 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka Pharmaceutical Development & Commercialization, INC. | $21.58 | 2025 | Rexulti |
| Napo Pharmaceuticals INC | $21.52 | 2023 | Mytesi |
| Abbott Laboratories | $16.00 | 2020 | |
| Radius Health, INC. | $15.92 | 2019 | |
| Novo Nordisk INC | $13.11 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kenneth Mills listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.